Liquid biopsy offers a non-invasive alternative for clinicians to identify clinically relevant biomarkers in patients to guide treatment decisions.

A liquid biopsy test looks for cancer cells or DNA fragments (cfDNA) from a tumour that is circulating in the blood. Obtaining blood samples is less invasive compared to traditional tissue biopsies.

What is a liquid biopsy based test?
Certain lung cancer patients are not good candidates for tissue biopsy as this is an invasive procedure that carries risk. Liquid biopsy offers a non-invasive alternative for clinicians to identify clinically relevant biomarkers in patients to guide treatment decisions.

A liquid biopsy test looks for cancer cells or DNA fragments (cfDNA) from a tumour that is circulating in the blood. Obtaining blood samples is less invasive compared to traditional tissue biopsies.

In NSCLC*, EGFR (Epidermal Growth Factor Receptor) testing is not performed in ~20% of eligible patients due to unavailable or insufficient tissue.

Liquid biopsy can help provide results to clinicians and their patients within 1 day.

Liquid biopsy can help overcome complications of a lung biopsy and is playing an increasingly important role as a companion diagnostics in cancer management.